{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:31:12Z","timestamp":1765632672340,"version":"3.48.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.seminhematol.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T15:43:04Z","timestamp":1763307784000},"page":"129-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates on current and future research in acute myeloid leukemia"],"prefix":"10.1053","volume":"62","author":[{"given":"Frederik","family":"Damm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.seminhematol.2025.10.001_bib0001","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.10.001_bib0002","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.10.001_bib0003","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.10.001_bib0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.10.001_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1053\/j.seminhematol.2025.10.001_bib0006","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1182\/blood-2010-08-303479","article-title":"Integrative prognostic risk score in acute myeloid leukemia with normal karyotype","volume":"117","author":"Damm","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0007","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","article-title":"The proteogenomic subtypes of acute myeloid leukemia","volume":"40","author":"Jayavelu","year":"2022","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.10.001_bib0008","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.10.001_bib0009","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.seminhematol.2025.08.002","article-title":"Germline predispositions to myeloid malignancies: Across the lifespan","volume":"62","author":"Atluri","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0011","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.seminhematol.2025.06.001","article-title":"The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies","volume":"62","author":"Duployez","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0012","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2025.06.005","article-title":"Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories","volume":"62","author":"Guarnera","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0013","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminhematol.2025.06.004","article-title":"Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications","volume":"62","author":"Croese","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.seminhematol.2025.06.003","article-title":"Epigenetic dysregulation in acute myeloid leukemia","volume":"62","author":"Schrezenmeier","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2025.08.001","article-title":"Menin inhibition for the treatment of acute leukemia","volume":"62","author":"Wenge","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0016","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.seminhematol.2025.09.001","article-title":"Tailoring intensive and less-intensive treatment in acute myeloid leukemia","volume":"62","author":"Seeling","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0017","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/j.seminhematol.2025.08.003","article-title":"The immunotherapy landscape in AML: Defining knowledge gaps toward rational combinatorial strategies","volume":"62","author":"Subklewe","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0018","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.seminhematol.2025.07.001","article-title":"Resolving leukemic stem cell heterogeneity and plasticity with single-cell multi-omics","volume":"62","author":"Huang","year":"2025","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0019","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.seminhematol.2025.06.002","article-title":"AML diagnostics in the 21st century: Use of AI","volume":"62","author":"Haferlach","year":"2025","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.10.001_bib0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-024-01590-1","article-title":"Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients","volume":"17","author":"Halik","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.10.001_bib0021","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/bjh.20027","article-title":"The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML","volume":"206","author":"Stasik","year":"2025","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.10.001_bib0022","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.10.001_bib0023","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41375-024-02501-6","article-title":"A novel prognostic risk model for patients with refractory\/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents","volume":"39","author":"Shahswar","year":"2025","journal-title":"Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:27:30Z","timestamp":1765632450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0037196325000459"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.10.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on current and future research in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}